Amid the rush for a SARS-CoV-2 vaccine to deal with the COVID-19 pandemic, a robust risk assessment must be conducted, and mitigation strategies applied.
Soumya Paul
Advertisement
Soumya Paul is CEO at Pentavalent Biosciences.
Articles by Soumya Paul
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
4
$1.8M RedHill Deal Highlights Growing Worldwide Focus on H. pylori Treatment Access
5
